---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-088218"
form_type: "8-K"
ticker: "PBH"
cik: "0001295947"
company_name: "Prestige Consumer Healthcare Inc."
filed_at: "2021-07-01T23:59:59+00:00"
generated_at: "2026-06-30T07:53:14.725215+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prestige completes $230M acquisition of TheraTears from Akorn, refinances term loan.

## Summary
- Acquired TheraTears and other OTC brands from Akorn Operating Company for $230M cash, closed July 1, 2021.
- Deal expected to add ~$60M annual revenue, ~$0.10 EPS, ~$13M operating cash flow.
- Expected annual EBITDA ~$20M, tax benefits ~$30M; transaction valued at <10x pro-forma EBITDA.
- Financed via cash, ABL revolver, and new $600M Term B-5 Loans (LIBOR+2%, floor 0.5%, maturity 2028).
- Announced Q1 fiscal 2022 earnings release scheduled for August 5, 2021, conference call at 8:30 a.m. ET.

## SEC filing metadata
- accession: 0001104659-21-088218
- form_type: 8-K
- ticker: PBH
- cik: 0001295947
- company_name: Prestige Consumer Healthcare Inc.
- filed_at: 2021-07-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1295947/000110465921088218/0001104659-21-088218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1295947/000110465921088218/tm2121213d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-088218
- JSON: https://secwatch.observer/filing/0001104659-21-088218.json
- Plain text: https://secwatch.observer/filing/0001104659-21-088218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.